Mark Mallon's most recent trade in Neogenomics Inc. was a trade of 347,777 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 1, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neogenomics Inc | Mark Mallon | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 347,777 | 347,777 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc | Mark Mallon | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 142,457 | 368,051 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc | Mark Mallon | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2021 | 152,858 | 225,594 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc | Mark Mallon | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 30.63 per share. | 06 Dec 2021 | 17,000 | 72,736 (0%) | 0% | 30.6 | 520,710 | Common Stock |
| Neogenomics Inc | Mark Mallon | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2021 | 151,016 | 151,016 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc | Mark Mallon | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2021 | 55,736 | 55,736 (0%) | 0% | 0 | Common Stock |